356 related articles for article (PubMed ID: 37479496)
1. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1-treatment of granulomatosis with polyangiitis and microscopic polyangiitis.
Schirmer JH; Sanchez-Alamo B; Hellmich B; Jayne D; Monti S; Luqmani RA; Tomasson G
RMD Open; 2023 Jul; 9(3):. PubMed ID: 37479496
[TBL] [Abstract][Full Text] [Related]
2. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV.
Sanchez-Alamo B; Schirmer JH; Hellmich B; Jayne D; Monti S; Tomasson G; Luqmani RA
RMD Open; 2023 Jun; 9(2):. PubMed ID: 37349121
[TBL] [Abstract][Full Text] [Related]
3. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Hellmich B; Sanchez-Alamo B; Schirmer JH; Berti A; Blockmans D; Cid MC; Holle JU; Hollinger N; Karadag O; Kronbichler A; Little MA; Luqmani RA; Mahr A; Merkel PA; Mohammad AJ; Monti S; Mukhtyar CB; Musial J; Price-Kuehne F; Segelmark M; Teng YKO; Terrier B; Tomasson G; Vaglio A; Vassilopoulos D; Verhoeven P; Jayne D
Ann Rheum Dis; 2024 Jan; 83(1):30-47. PubMed ID: 36927642
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
6. How best to manage relapse and remission in ANCA-associated vasculitis.
Puéchal X; Guillevin L
Expert Rev Clin Immunol; 2022 Nov; 18(11):1135-1143. PubMed ID: 36102147
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
8. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in ANCA-Associated Vasculitis.
Hassan RI; Gaffo AL
Curr Rheumatol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155022
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
11. ANCA-Associated Vasculitis: Core Curriculum 2020.
Geetha D; Jefferson JA
Am J Kidney Dis; 2020 Jan; 75(1):124-137. PubMed ID: 31358311
[TBL] [Abstract][Full Text] [Related]
12. Treatment Approaches to Granulomatosis with Polyangiitis and Microscopic Polyangiitis.
Berti A; Cornec D; Dua AB
Rheum Dis Clin North Am; 2023 Aug; 49(3):545-561. PubMed ID: 37331732
[TBL] [Abstract][Full Text] [Related]
13. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
[No Abstract] [Full Text] [Related]
14. CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum.
Turgeon D; Bakowsky V; Baldwin C; Cabral DA; Clements-Baker M; Clifford A; Cohen Tervaert JW; Dehghan N; Ennis D; Famorca L; Fifi-Mah A; Girard LP; Lefebvre F; Liang P; Makhzoum JP; Massicotte-Azarniouch D; Mendel A; Milman N; Reich HN; Robinson DB; Ross C; Rumsey DG; Soowamber M; Towheed TE; Trudeau J; Twilt M; Yacyshyn E; Yardimci GK; Khalidi N; Barra L; Pagnoux C
Rheumatology (Oxford); 2023 Aug; 62(8):2646-2651. PubMed ID: 36805625
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
Watanabe R; Oshima M; Nishioka N; Sada KE; Nagasaka K; Akiyama M; Ando T; Higuchi T; Inoue Y; Kida T; Mutoh T; Nakabayashi A; Onishi A; Sakai R; Waki D; Yamada Y; Yajima N; Tamura N; Kaname S; Harigai M
Mod Rheumatol; 2023 Aug; 33(5):982-989. PubMed ID: 36112482
[TBL] [Abstract][Full Text] [Related]
16. [Update on treatment of ANCA-associated vasculitis: Granulomatosis with polyangiitis and Microscopic Polyangiitis].
Holle JU; Hellmich B; Moosig F
Z Rheumatol; 2022 May; 81(4):280-285. PubMed ID: 35061059
[TBL] [Abstract][Full Text] [Related]
17. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Sejismundo LP; Mieras K; Iklé D; Jepson B; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheum; 2013 Sep; 65(9):2441-9. PubMed ID: 23754238
[TBL] [Abstract][Full Text] [Related]
19. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
20. [ANCA-associated vasculitis].
Krasselt ML; Holle JU
Inn Med (Heidelb); 2022 Sep; 63(9):947-960. PubMed ID: 35925127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
